Due to its diverse biological activities, dysfunction of ANP32A was already associated with other neurodegenerative-related diseases such as Alzheimer’s disease [22] or Spinocerebellar ataxia [23] and was also discussed as a potential therapeutic target [24,25,26]. This evidence concerns the gene ANP32A and early-onset autosomal dominant Alzheimer disease.